Product/Composition:- | Sofosbuvir,velpatasvir |
---|---|
Strength:- | Sofosbuvir 400 mg + Velpatasvir 100 mg |
Form:- | Tablet |
Reference Brands:- | Epclusa® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sofosbuvir + Velpatasvir tablets are a highly effective, once-daily oral antiviral treatment for chronic Hepatitis C infection, covering all major genotypes (1-6). This fixed-dose combination inhibits HCV replication by targeting NS5B polymerase and NS5A proteins. Available as 400 mg Sofosbuvir and 100 mg Velpatasvir tablets, it meets stringent EU-GMP and USFDA quality standards. Ideal for pharma B2B supply, hospital tenders, and licensing, this therapy offers high cure rates with a favorable safety profile and supports fast market registration in EU and US.
Sofosbuvir and Velpatasvir tablets are a potent, once-daily fixed-dose combination used for treating chronic Hepatitis C virus (HCV) infection across all major genotypes (1-6). Sofosbuvir, an NS5B polymerase inhibitor, combined with Velpatasvir, an NS5A inhibitor, effectively blocks viral replication and assembly. Available as oral tablets containing 400 mg Sofosbuvir and 100 mg Velpatasvir, these medications are manufactured under EU-GMP and USFDA standards, ensuring high quality and safety. Widely used in hospital tenders, B2B supply, and licensing, this therapy supports rapid market registration and global distribution.